SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Houssiau, F.
Right arrow Articles by Ginzler, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Houssiau, F.
Right arrow Articles by Ginzler, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

review-article

Current treatment of lupus nephritis

FA Houssiau

Rheumatology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium

EM Ginzler

Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, New York, USA

This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the current options for induction and maintenance therapy. The respective place of mycophenolate mofetil and intravenous cyclophosphamide are balanced, taking into account efficacy, safety and patients’ perspective. The authors anticipate that, in a few years, when long-term data on lupus nephritis patients induced with mycophenolate mofetil becomes available, it is probably that intravenous cyclophosphamide, which has been for so long the ‘standard of care’, will be prescribed only in specialized conditions such as documented necrotizing vasculitis.

Lupus, Vol. 17, No. 5, 426-430 (2008)
DOI: 10.1177/0961203308090029
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. N. Boletis, S. Marinaki, C. Skalioti, S. S. Lionaki, A. Iniotaki, and P. P. Sfikakis
Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2157 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. H. M. Berden
Azathioprine, the Cinderella in the treatment of lupus nephritis
Nephrol. Dial. Transplant., June 9, 2009; (2009) gfp241v1.
[Full Text] [PDF]

Home page
 LupusHome page
M. Kriegel, C Van Beek, A Mostaghimi, and V. Kyttaris
Sterile empyematous pleural effusion in a patient with systemic lupus erythematosus: a diagnostic challenge
Lupus, June 1, 2009; 18(7): 581 - 585.
[Abstract] [PDF]

Home page
 CJASNHome page
C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al.
Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome
Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587.
[Abstract] [Full Text] [PDF]


Advertisement